Candel Therapeutics (CADL) Stock Price, News & Analysis

Company Overview

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications. The company’s research and development activities are supported by a combination of in-house expertise in viral immunology and collaborations with academic institutions and contract research organizations. Preclinical studies have demonstrated the potential of Candel’s viral platforms to reshape the tumor microenvironment and synergize with checkpoint inhibitors and other immunotherapies.

Headquartered in Pittsburgh, Pennsylvania, Candel Therapeutics conducts clinical trials across multiple sites in North America and Europe. The company was founded by scientists with deep expertise in oncolytic virotherapy and has assembled a management team experienced in advancing viral therapies through regulatory interactions. As a public company listed on Nasdaq under the ticker CADL, Candel continues to expand its scientific capabilities and clinical footprint to bring innovative viral immunotherapies to patients worldwide.

Key Stats

• Today's Range: $5.41 to $5.51
• 50-Day Range: $4.79 to $6.57
• 52-Week Range: $3.79 to $14.60
• Volume: 49,156 shs
• Average Volume: 989,671 shs
• Market Capitalization: $302.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Moderate Buy

Candel Therapeutics Stock Analysis - MarketRank™

Candel Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 586th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Candel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Candel Therapeutics has a consensus price target of $20.00, representing about 264.9% upside from its current price of $5.48.

Amount of Analyst Coverage

Candel Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Candel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Candel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Candel Therapeutics has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.67% of the float of Candel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Candel Therapeutics has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Candel Therapeutics has recently increased by 2.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Candel Therapeutics does not currently pay a dividend.

Dividend Growth

Candel Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.67% of the float of Candel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Candel Therapeutics has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Candel Therapeutics has recently increased by 2.20%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.48

News Sentiment

Candel Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Candel Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for CADL on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

3 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,540.00 in company stock.

Percentage Held by Insiders

16.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.93% of the stock of Candel Therapeutics is held by institutions.

CADL Stock Analysis - Frequently Asked Questions

How have CADL shares performed this year?

Candel Therapeutics' stock was trading at $8.68 at the beginning of the year. Since then, CADL shares have decreased by 36.9% and is now trading at $5.4810.

How were Candel Therapeutics' earnings last quarter?

Candel Therapeutics, Inc. (NASDAQ:CADL) issued its earnings results on Thursday, August, 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08.

When did Candel Therapeutics IPO?

Candel Therapeutics (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

How do I buy shares of Candel Therapeutics?

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Candel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CADL
• CIK: 1841387
• Web: www.candeltx.com
• Phone: 617-916-5445
• Fax: N/A
• Employees: 60
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Candel Therapeutics: $20.00
• High Price Target: $25.00
• Low Price Target: $7.00
• Potential Upside/Downside: +265.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.18 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.00%
• Return on Assets: -26.81%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 7.04
• Quick Ratio: 7.04

Sales & Book Value

• Annual Sales: $120 thousand
• Price / Sales: 2,502.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 3.88

Miscellaneous

• Outstanding Shares: 54,900,000
• Free Float: 45,782,000
• Market Cap: $300.30 million
• Optionable: Optionable
• Beta: -0.94